Sugi Predict

Sugi Predict / Compounds / SCHEMBL31129652

SCHEMBL31129652

SCHEMBL31129652

Cn1c(=O)n(C2CCC(=O)NC2=O)c2ccc(N3CCC(CC4CCN(C(=O)OC(C)(C)C)CC4)CC3)cc21

nearest known ligand 0.51

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 11/20 0.51
▸ CRBN Q96SW2 11/20 0.51
▸ GPR119 Q8TDV5 8/20 0.42
▸ PIK3CA P42336 1/20 0.39
▸ PRKDC P78527 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31129430 0.95 CRBN (0.47) DDB1CRBNGPR119PIK3CAPRKDC
SCHEMBL31281850 0.95 DDB1 (0.49) DDB1CRBNGPR119PIK3CAPRKDC
SCHEMBL31129595 0.93 DDB1 (0.46) DDB1CRBNGPR119PIK3CAPRKDC
SCHEMBL23541316 0.93 DDB1 (0.51) DDB1CRBNGPR119
SCHEMBL31281929 0.92 DDB1 (0.47) DDB1CRBNGPR119PIK3CAPRKDC
SCHEMBL31129479 0.92 CRBN (0.46) DDB1CRBNPIK3CAPRKDC
SCHEMBL22835971 0.92 DDB1 (0.55) DDB1CRBNGPR119
SCHEMBL30768477 0.92 DDB1 (0.55) DDB1CRBNGPR119
SCHEMBL30768650 0.92 DDB1 (0.55) DDB1CRBNGPR119
SCHEMBL31282043 0.91 CRBN (0.49) DDB1CRBNGPR119PIK3CAPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO ARVINAS OPERATIONS, INC. (US) 2026-04-23 — — US disclosed
US-12599672-B2 KRAS proteolysis targeting chimeras PAQ Therapeutics Inc. (US) 2026-04-14 — — US disclosed
US-20260098049-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-04-09 — — US disclosed
EP-4655073-A2 CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO Arvinas Operations, Inc. (US) 2025-12-03 — — EP disclosed
US-12448399-B2 Cereblon-based KRAS degrading PROTACs and uses related thereto ARVINAS OPERATIONS, INC. (US) 2025-10-21 — — US disclosed
US-20250144225-A1 KRAS Proteolysis Targeting Chimeras PAQ Therapeutics Inc. (US) 2025-05-08 — — US disclosed
WO-2025076044-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS PAQ Therapeutics Inc. (US) 2025-04-10 — — WO disclosed
WO-2024159164-A2 CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO ARVINAS OPERATIONS, INC. (US) 2024-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12599672-B2 KRAS proteolysis targeting chimeras KRAS, HRAS, NRAS DDB1 735/4885CRBN 13/4885GPR119 4051/4885
US-12448399-B2 Cereblon-based KRAS degrading PROTACs and uses related thereto CRBN, KRAS, WEE1 DDB1 1314/4885CRBN 1/4885GPR119 3564/4885
US-20250144225-A1 KRAS Proteolysis Targeting Chimeras KRAS, HRAS, NRAS DDB1 966/4885CRBN 49/4885GPR119 2414/4885
US-20260098049-A1 KRAS MODULATING COMPOUNDS KRAS, NRAS, HRAS DDB1 992/4885CRBN 179/4885GPR119 2528/4885
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO KRAS, CRBN, HRAS DDB1 1105/4885CRBN 2/4885GPR119 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.